Posted: June 15th, 2012 | Company/topic: Merck
Website: InPharm
Merck’s novel insomnia drug suvorexant has improved patients’ ability to fall asleep, according to new data from two Phase III trials. The manufacturer says this means it is on track to fi…
Merck & Co Inc said its experimental insomnia drug maintained effectiveness for twelve months in a late-stage study, the first sleep aid ever tested for a full year, and reaffirmed it plans in 201…
